Active	Status	Sponsor type	Region	Phase	Filter
17 Active 0 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

17 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lindsey, Stephen
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)	Recruiting	4	350	Europe, Japan, US, RoW	Belimumab (GSK1550188), BEL (BENLYSTA)	GlaxoSmithKline	Systemic Lupus Erythematosus	04/27	05/29
COVER-CoAd, NCT05543642: The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients	Active, not recruiting	4	129	US	Hepatitis A vaccine, Havrix, Diphtheria, pertussis, and tetanus booster vaccine, Boostrix	Oregon Health and Science University	Rheumatic Diseases	01/25	12/25
SIRIUS-SLE 2, NCT05624749 / 2022-002690-29: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus	Recruiting	3	280	Europe, US, RoW	ianalumab, VAY736, placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Systemic Lupus Erythematosus	01/27	01/29
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30
Mendez, Katherin
SIRIUS-SLE 1, NCT05639114 / 2022-002691-36: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus	Recruiting	3	406	Europe, Canada, Japan, US, RoW	Ianalumab, VAY736, Placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Systemic Lupus Erythematosus	01/27	04/29
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30
ROBUST, NCT05675046: Multicenter Prospective Trial of Office-based Carpal Tunnel Release With Ultrasound Guidance	Active, not recruiting	N/A	149	US	Ultrasound Guided Carpal Tunnel Release (CTR-US), UltraGuideCTR	Sonex Health, Inc.	Carpal Tunnel Syndrome, CTS	09/23	12/25
Chatham, Walter Winn
NCT04362111: Early Treatment of Cytokine Storm Syndrome in Covid-19	Completed	3	32	US	Anakinra, recombinant human IL-ra (rhIL-1ra), Normal saline, NS	University of Alabama at Birmingham	Cytokine Storm, COVID-19	12/21	06/23
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis	Terminated	3	275	Europe, Canada, Japan, US, RoW	secukinumab, AIN457, Placebo	Novartis Pharmaceuticals	Lupus Nephritis	09/23	09/23
SIRIUS-SLE 1, NCT05639114 / 2022-002691-36: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus	Recruiting	3	406	Europe, Canada, Japan, US, RoW	Ianalumab, VAY736, Placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Systemic Lupus Erythematosus	01/27	04/29
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30
NCT02780583: Treatment of Macrophage Activation Syndrome (MAS) With Anakinra	Terminated	1	9	US	kineret, Anakinra, placebo, normal saline	University of Alabama at Birmingham	Macrophage Activation Syndrome	03/23	04/24
Osman, Yahya
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30
Rashid, Danial
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30
Sedillo, Anthony
NCT06333990: Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)	Recruiting	3	146	US	Quetiapine Fumarate, Seroquel, TAU, Treatment As Usual	Foundation for Advancing Veterans' Health Research, The University of Texas Health Science Center at San Antonio, Biomedical Research Institute of New Mexico	Mild Traumatic Brain Injury	06/28	06/28
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30
Zhuang, Yanni
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30